Drug Profile
GRC 388XX
Alternative Names: GRC388XXLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Anti-inflammatories; Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Idiopathic pulmonary fibrosis
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in India (unspecified route)
- 27 Sep 2023 Discontinued - Preclinical for Idiopathic pulmonary fibrosis in India (unspecified route)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in India